MANAGEMENT OF CHRONIC MYELOID-LEUKEMIA IN CHRONIC PHASE WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION AND ALPHA-2 INTERFERON - CYTOGENETIC AND CLINICAL-RESULTS

被引：7

作者：

ALIMENA, G

MELONI, G

DECUIA, MR

RONDINELLI, MB

LOCOCO, F

MONTEFUSCO, E

MANCINI, M

PINTO, R

NANNI, M

CEDRONE, M

DEFABRITIIS, P

MANDELLI, F

机构：

[1] Section of Hematology, Department of Human Biopathology, University of Rome La Sapienza, Rome

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 11卷

关键词：

ASCT; ALPHA-2; IFN; CML; CYTOGENETICS;

D O I：

10.3109/10428199309047900

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and alpha Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance. Following ASCT, a major karyotype response (more than 65% Ph1 negative cells, MKR) was observed at least once in 40%, 53% and 83% of patients from the three groups, respectively. At last follow-ups (median 39, 40 and 21 months, respectively) 19%, 13% and 67% of patients still present a MKR with 2 patients from group 1 and 4 patients from group 3 being 100% Ph' negative. Projected survival from diagnosis is 77% at 52 months for patients from group 1 and 47% at 75 months for patients from group 2. Present data indicate that 1) IFN can stabilize results obtained with ASCT, 2) ASCT can potentiate responses to IFN, 3) combined ASCT and IFN can improve survival. Longer follow-up of patients and randomized studies are required to define the real impact on disease outcome by these treatment approaches.

引用

页码：281 / 291

页数：11

共 23 条

[11]

De Fabritiis P., Sandrelli A., Meloni G., Alimena G., Montefusco E., Lo Coco F., De Felice L., Mandelli F., Prolonged suppression of myeloid progenitor cell numbers after stopping interferon treatment for CML may necessitate delay in harvesting marrow cells for autografting, Bone Marrow Transplant, 6, pp. 247-251, (1990)

[12]

Lo Coco F., Mandelli F., Diverio D., Alimena G., De Fabritiis P., Meloni G., Cedrone M., Frontani M., Guerrasio A., Saglio G., Therapy-induced Ph<sup>1</sup> suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion, Bone Marrow Transplant, 6, pp. 253-258, (1990)

[13]

Sokal J.E., Baccarani M., Tura S., Gomez J.A., Robertson J.E., Tsao C.Y., Braun T.J., Clarkson B.D., Cervantes F., Rozman C., The Italian Cooperative CML Study Group, Prognostic discrimination in good-risk chronic granulocytic leukemia, Blood, 63, pp. 789-799, (1984)

[14]

Alimena G., Montefusco E., Mancini M., De Fabritiis P., Cedrone M., Sandrelli A., Mandelli F., Prolonged effect of alpha-interferon after discontinuance of treatment in chronic myelogenous leukemia patients, Eur. J. Haematol., 43, pp. 108-111, (1989)

[15]

Goldman J.M., Th'ng K.H., Park D.S., Spiers A.S.D., Lowenthal R.M., Ruutu T., Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in transformation, Br. J. Haematol., 40, pp. 185-191, (1978)

[16]

Buckner C.D., Clift R.A., Fefer A., Neiman P.E., Storb R., Thomas E.D., Treatment of blastic transformation of chronic granulocytic leukemia by high dose cyclophosphamide, total body irradiation and infusion of cryopreserved autologous marrow, Exp. Haematol., 4, (1974)

[17]

Melini G., Pulsoni A., De Fabritiis P., Malagnino F., Montefusco E., Papa G., Sandrelli A., Simone F., Mandelli F., Autologous bone marrow transplantation (ABMT) for patients with chronic granulocytic leukemia (CGL) in blastic phase (BP), Exp. Haematol., 13, pp. 17-47, (1985)

[18]

Haines M.E., Goldman J.M., Worsley A.M., McCarthy D.M., Wyatt S.E., Dowding C., Kearney L., Th'ng K.H., Wareham N.J., Pollock A., Galvin M.C., Samson D., Geary C.G., Catovsky D., Galton D.A.G., Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients, Br. J. Haematol., 58, pp. 711-714, (1984)

[19]

Reiffers J., Trouette R., Marit G., Montastruc M., Faberes C., Cony-Makhoul P., David B., Bourdeau M.J., Bilhou-Nabera C., Lacombe F., Feuillatre-Fabre F., Vezon G., Bernard P., Broustet A., Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases, Br. J. Haematol., 77, pp. 339-345, (1991)

[20]

Brito-Babapulle F., Bowcock S.J., Marcus R.E., Apperley J., Th'ng K.H., Dowding C., Rassol F., Guo A., Catowsky D., Galton D.A.G., McCarthy D., Goldman J.M., Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haemopoiesis, Br. J. Haematol., 73, pp. 76-81, (1989)

← 1 2 3 →